CVS Health Corporation $CVS Stock Sold by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC lowered its stake in shares of CVS Health Corporation (NYSE:CVS) by 15.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 240,188 shares of the pharmacy operator’s stock after selling 43,924 shares during the quarter. Douglas Lane & Associates LLC’s holdings in CVS Health were worth $20,582,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Stableford Capital II LLC purchased a new position in shares of CVS Health during the 3rd quarter worth approximately $687,000. Mn Services Vermogensbeheer B.V. boosted its position in shares of CVS Health by 1.3% during the third quarter. Mn Services Vermogensbeheer B.V. now owns 375,568 shares of the pharmacy operator’s stock valued at $32,182,000 after purchasing an additional 4,900 shares in the last quarter. Farther Finance Advisors LLC grew its stake in CVS Health by 30.6% in the third quarter. Farther Finance Advisors LLC now owns 54,244 shares of the pharmacy operator’s stock worth $4,648,000 after purchasing an additional 12,718 shares during the period. CoreCap Advisors LLC raised its holdings in CVS Health by 50.6% in the third quarter. CoreCap Advisors LLC now owns 5,242 shares of the pharmacy operator’s stock worth $449,000 after purchasing an additional 1,761 shares in the last quarter. Finally, Artemis Investment Management LLP lifted its position in CVS Health by 65.6% during the third quarter. Artemis Investment Management LLP now owns 50,481 shares of the pharmacy operator’s stock valued at $4,326,000 after buying an additional 20,000 shares during the period. Institutional investors own 80.66% of the company’s stock.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Long-term drug-distribution agreements extended: CVS renewed pharmaceutical distribution contracts with Cardinal Health and McKesson through 2032, supporting supply continuity for its retail pharmacies and other dispensing channels. What Does CVS Health Gain From Extending Its Drug Distribution Deals to 2032?
• Positive Sentiment: Aetna still reports broad four-star coverage: More than 69% of Aetna Medicare Advantage members are enrolled in plans rated four stars or higher for 2027. CVS says the results reflect solid clinical quality and member experience, which could help support enrollment and reimbursement in much of the business. Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience
• Neutral Sentiment: Pharmacy-focused store opens in Boston: CVS launched its first pharmacy-only location in the Boston area, emphasizing prescriptions, vaccinations and pharmacist-led care. The smaller format may improve access and lower operating requirements, although the immediate financial impact is unclear. CVS Opens First Pharmacy-Focused Location in Boston Area
• Negative Sentiment: Medicare Advantage ratings are the key concern: TD Cowen estimates the share of CVS’s Medicare Advantage members in plans rated at least 4.5 stars could fall to about 35% from 63%. Analysts warn that the setback could pressure bonus payments, margins and Aetna’s competitive position, particularly as Humana benefits from improved ratings. TD Cowen Warns of Bottom-Line Pressure Amid Star Ratings Setback
• Negative Sentiment: Investors remain focused on healthcare profitability: Rising healthcare spending does not necessarily translate into stronger earnings, as medical costs, government reimbursement and regulation can limit insurers’ margins. That backdrop amplifies concerns about CVS’s Medicare Advantage performance. Seniors Face an 18% Drop in Highly Rated Medicare Advantage Plans

Analyst Ratings Changes

CVS has been the subject of several research reports. Sanford C. Bernstein reiterated an “outperform” rating and issued a $112.00 price target on shares of CVS Health in a research note on Wednesday, September 9th. Wells Fargo & Company upped their price objective on shares of CVS Health from $103.00 to $123.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Robert W. Baird set a $107.00 target price on shares of CVS Health in a report on Thursday, August 6th. Argus boosted their price target on CVS Health from $104.00 to $114.00 and gave the stock a “buy” rating in a research report on Wednesday, August 19th. Finally, Weiss Ratings raised CVS Health from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 5th. Twenty-one equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, CVS Health currently has a consensus rating of “Moderate Buy” and an average price target of $107.24.

CVS Health Stock Down 0.9%

Shares of NYSE:CVS traded down $0.79 during trading on Friday, reaching $87.01. 5,590,040 shares of the stock traded hands, compared to its average volume of 8,288,887. The stock has a market cap of $111.28 billion, a P/E ratio of 23.03, a price-to-earnings-growth ratio of 0.82 and a beta of 0.60. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. The stock has a 50-day moving average of $93.10 and a two-hundred day moving average of $92.41. CVS Health Corporation has a 52-week low of $69.51 and a 52-week high of $110.68.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. During the same period in the previous year, the business earned $1.81 EPS. The firm’s revenue for the quarter was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, sell-side analysts expect that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Thursday, October 22nd will be given a dividend of $0.6650 per share. The ex-dividend date of this dividend is Thursday, October 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.1%. CVS Health’s dividend payout ratio (DPR) is 70.37%.

About CVS Health

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company’s major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.